In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BenevolentAI Limited

https://www.benevolent.com/

Latest From BenevolentAI Limited

Mismatched Tech And Demand Behind Korea’s Slow Pharma AI Progress

The new head of South Korea’s AI Drug Development Support Center talks about the country’s activities and market trends in the field, why the otherwise tech-savvy country is still lagging and what is needed to boost collaboration and the availability of big data.

South Korea Artificial Intelligence

5 Dealmaking Trends To Watch In 2022

2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?

Deals Companies

Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital

Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs. 

Financing Innovation

Seismic Hopes To Shake Up Immunology With New Financing

Financing Snapshot: The AI/ML-focused company raised $101m in a series A round and plans to use the funding to develop immunoglobulin- and cell-mediated autoimmune disorder drugs.

Financing Artificial Intelligence
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Digital Health
    • Artificial Intelligence
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • BenevolentBio, BenevolentTech
UsernamePublicRestriction

Register